Go Pro

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Oric Pharmaceuticals logo
$12.99 -0.25 (-1.89%)
As of 04:00 PM Eastern

Oric Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
13

Based on 15 Wall Street analysts who have issued ratings for Oric Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 1 has given a hold rating, and 13 have given a buy rating for ORIC.

Consensus Price Target

$19.45
49.77% Upside
According to the 15 analysts' twelve-month price targets for Oric Pharmaceuticals, the average price target is $19.45. The highest price target for ORIC is $27.00, while the lowest price target for ORIC is $14.00. The average price target represents a forecasted upside of 49.77% from the current price of $12.99.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ORIC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Oric Pharmaceuticals and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORIC Analyst Ratings Over Time

TypeCurrent Forecast
8/31/25 to 8/31/26
1 Month Ago
8/1/25 to 8/1/26
3 Months Ago
6/2/25 to 6/2/26
1 Year Ago
8/31/24 to 8/31/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.45$19.27$19.36$17.63
Forecasted Upside49.77% Upside74.10% Upside154.12% Upside72.29% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ORIC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ORIC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Oric Pharmaceuticals Stock vs. The Competition

TypeOric PharmaceuticalsHealthcare CompaniesBroader Market
Consensus Rating Score
2.80
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside46.94% Upside851.09% Upside13.05% Upside
News Sentiment Rating
Positive News

See Recent ORIC News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/10/2026
HC Wainwright logo
HC Wainwright
4 of 5 stars
Robert Burns
4 of 5 stars
Boost TargetBuy$25.00 ➝ $27.00+100.00%
7/17/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 Reiterated RatingSell (D-)
6/12/2026
Stifel Nicolaus logo
Stifel Nicolaus
4 of 5 stars
 Initiated CoverageBuy$14.00+77.69%
6/8/2026 Reiterated RatingBuy
5/22/2026 Reiterated RatingOverweight
5/15/2026UpgradeNeutralBuy$15.00+79.86%
5/5/2026Lower TargetBuy$17.00 ➝ $16.00+72.73%
4/1/2026Lower TargetOutperform$20.00 ➝ $17.00+34.18%
2/24/2026Reiterated RatingOutperform$15.00+28.10%
1/7/2026Initiated CoverageOverweight$22.00+170.27%
Ready to give options a try? Your first trade (Ticker included) -INSIDE (Ad)

Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel

12/8/2025Boost TargetOverweight$19.00 ➝ $25.00+127.27%
11/20/2025Initiated CoverageOutperform$25.00+117.77%
11/18/2025Boost TargetOverweight$17.00 ➝ $20.00+70.95%
11/18/2025Initiated CoveragePeer Perform
9/4/2025Initiated CoverageBuy$18.00+69.81%
8/12/2025 UpgradeHold
7/8/2025Initiated CoverageBuy$15.00+40.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:01 PM ET.


ORIC Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Oric Pharmaceuticals is $19.45, with a high forecast of $27.00 and a low forecast of $14.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oric Pharmaceuticals in the last year. There is currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ORIC shares.

According to analysts, Oric Pharmaceuticals's stock has a predicted upside of 49.77% based on their 12-month stock forecasts.

Oric Pharmaceuticals has been rated by research analysts at Benchmark, HC Wainwright, Stifel Nicolaus, and Weiss Ratings in the past 90 days.

Analysts like Oric Pharmaceuticals more than other "healthcare" companies. The consensus rating for Oric Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ORIC compares to other companies.


MarketBeat monitors more than a dozen sources for Oric Pharmaceuticals analyst ratings, with the most recent rating issued on 8/10/2026.
From Our Partners